

Magle Group appoints new Chief Marketing and Innovation Officer

Magle Group (Nasdaq Stockholm First North Growth Market: MAGLE) today announces the appointment of Helena Ossmer Thedius as Chief Marketing and Innovation Officer. She will be responsible for the global marketing of Magle Group's proprietary medical products and will also be instrumental in exploiting the company's cutting-edge material science to further expand the product portfolio.

Helena Ossmer Thedius is a seasoned life-science industry leader who has held various senior roles before joining Magle Group, most recently as Marketing & Innovation Director at the oral health company TePe Oral Hygiene Products, Sweden. Across her career, she has led teams through product development and has been responsible for developing global marketing and brand initiatives and overseeing their implementation. In addition, Helena has experience in various companies and brings a wealth of knowledge as well as an extensive network to her new position at Magle Group.

"Helena Ossmer Thedius has a strong track record of success and her insights and experience are exactly what we need to propel the company forward as we embark on our expansion journey. Helena will be a key person to help us convert our strategic potential into company value for all stakeholders. I am excited to welcome her to the team, and I look forward to us growing the awareness of our brand and medical device products globally," said Justin Pierce, CEO of Magle Group.

"I am really excited to be joining Magle Group and bringing my experience of marketing, product development and global product strategies to the team. I see a substantial commercial potential in the company's current portfolio of unique medical products, which constitutes a solid foundation for its long-term expansion strategy," comments Helena Ossmer Thedius.

Helena Ossmer Thedius will join Magle Group in late September 2022 and report to CEO Justin Pierce.

Contacts

Megi Medzmariashvili, Legal Counsel, phone +46 (0)76 164 33 12, megi.medzmariashvili@maglechemoswed.com

About Us

The Magle Group aims to establish itself as a leader in high-quality life-changing healthcare innovations to meet medical needs through scientific excellence. The Magle Group is founded on strategic acquisitions aimed at driving growth and diversifying risk. Today, the Group includes two operational areas. Magle Chemoswed – a contract development and manufacturing organization (CDMO) with a strong reputation for its high-quality development and manufacturing expertise and Magle PharmaCept – an established sales and marketing company for development and direct sales of the Groups medical technology products. Learn more on www.maglechemoswed.com and <https://maglegroup.com/> and www.maglepharmaceut.com

Västra Hamnen Corporate Finance is the Company's certified advisor on Nasdaq First North Growth Market and can be reached at ca@vhcorp.se or +46 (0) 40 200 250.

Attachments

[Magle Group appoints new Chief Marketing and Innovation Officer](#)